Ovid Therapeutics (OVID) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Annual meeting scheduled for June 10, 2026, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials and vote by June 9, 2026.
Voting matters and shareholder proposals
Election of Jeremy M. Levin, DPhil, MB BChir, as Class III director is up for vote.
Advisory vote on executive compensation for named executive officers is included.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Board recommends voting in favor of all proposals.
Board of directors and corporate governance
Board has nominated Jeremy M. Levin for election as Class III director.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Ovid Therapeutics
- Advanced pipeline, higher net loss, and strong cash position support future operations.OVID
Q2 2026 - Advancing differentiated neurotherapeutics for epilepsy and psychosis with strong clinical momentum.OVIDCorporate presentation
- Multiple clinical milestones and strong financial runway position the pipeline for significant value creation.OVID7th Annual HCW Neuro Perspectives Hybrid Conference
- All proposals passed, including director election and auditor ratification, with strong quorum.OVIDAGM 2026
- Net loss was $17.0M in Q1 2026; cash reserves and funding extend runway into 2029.OVIDQ1 2026
- Advancing novel therapies for seizures and psychosis with strong safety and market potential.OVIDCorporate presentation
- Director election, say-on-pay, auditor ratification, and governance updates headline the 2026 proxy.OVIDProxy filing
- Pipeline progress, strong safety, and financing extend cash runway into late 2028 or 2029.OVIDQ4 2025
- OV329 advances with biomarker-driven trials, aiming for safer, differentiated epilepsy therapy.OVIDStatus Update